DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
AGN-201904 is an investigational drug.
There have been 47 clinical trials for AGN-201904. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Rosacea, Keratoconjunctivitis Sicca, and Ocular Hypertension. The leading clinical trial sponsors are Allergan, Editas Medicine, Inc., and Naurex, Inc, an affiliate of Allergan plc.
There are two US patents protecting this investigational drug and forty-three international patents.
Recent Clinical Trials for AGN-201904
|A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease||Allergan||Phase 1/Phase 2|
|AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines||Allergan||Phase 2|
|Single Ascending Dose Study in Participants With LCA10||Editas Medicine, Inc.||Phase 1/Phase 2|
Top disease conditions for AGN-201904
Top clinical trial sponsors for AGN-201904
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AGN-201904||Start Trial||Prodrugs of proton pump inhibitors||Winston Pharmaceuticals, Inc. (Newport Beach, CA) The United States of America as represented by the Department of Veteran Affairs (Washington, DC) N/A (Oakland, CA) The Reagents of the University of California (N/A)||Start Trial|
|AGN-201904||Start Trial||Process for preparing isomerically pure prodrugs of proton pump inhibitors||Allergan, Inc. (Irvine, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|